These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 29275177)

  • 1. Synergistic therapeutic effect of diethylstilbestrol and CX-4945 in human acute T-lymphocytic leukemia cells.
    Jung JI; Park KY; Kim SA; Kim J
    Biomed Pharmacother; 2018 Feb; 98():357-363. PubMed ID: 29275177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro combinatorial anti-proliferative and immunosuppressive effects of Brucea javanica extract with CX-4945 and imatinib in human T-cell acute lymphoblastic leukemia cells.
    Jung JI; Kim SY; Park KY; Sydara K; Lee SW; Kim SA; Kim J
    Biomed Pharmacother; 2018 Oct; 106():403-410. PubMed ID: 29966986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.
    Buontempo F; Orsini E; Lonetti A; Cappellini A; Chiarini F; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; Bertacchini J; Neri LM; McCubrey JA; Martelli AM
    Oncotarget; 2016 Jan; 7(2):1323-40. PubMed ID: 26593250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Proliferative Effect of
    Kim J; Lee DH; Badamtsetseg B; Lee S; Kim SA
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33374788
    [No Abstract]   [Full Text] [Related]  

  • 5. Plumbagin exerts an immunosuppressive effect on human T-cell acute lymphoblastic leukemia MOLT-4 cells.
    Bae KJ; Lee Y; Kim SA; Kim J
    Biochem Biophys Res Commun; 2016 Apr; 473(1):272-277. PubMed ID: 27018383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
    Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
    BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells.
    Lian H; Li D; Zhou Y; Landesman-Bollag E; Zhang G; Anderson NM; Tang KC; Roderick JE; Kelliher MA; Seldin DC; Fu H; Feng H
    Haematologica; 2017 Jan; 102(1):e17-e21. PubMed ID: 27758824
    [No Abstract]   [Full Text] [Related]  

  • 8. Simultaneous Inhibition of Protein Kinase CK2 and Dihydrofolate Reductase Results in Synergistic Effect on Acute Lymphoblastic Leukemia Cells.
    Wińska P; Widło Ł; Skierka K; Krzyśko A; Koronkiewicz M; Cieśla JM; Cieśla J; Bretner M
    Anticancer Res; 2019 Jul; 39(7):3531-3542. PubMed ID: 31262877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.
    Buontempo F; Orsini E; Martins LR; Antunes I; Lonetti A; Chiarini F; Tabellini G; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Cappellini A; Barata JT; Martelli AM
    Leukemia; 2014 Mar; 28(3):543-53. PubMed ID: 24253024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The synergistic repressive effect of NF-κB and JNK inhibitor on the clonogenic capacity of Jurkat leukemia cells.
    Liu X; Zhang J; Li J; Volk A; Breslin P; Zhang J; Zhang Z
    PLoS One; 2014; 9(12):e115490. PubMed ID: 25526629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LYG-202 augments tumor necrosis factor-α-induced apoptosis via attenuating casein kinase 2-dependent nuclear factor-κB pathway in HepG2 cells.
    Chen FH; Lu N; Zhang HW; Zhao L; He LC; Sun HP; You QD; Li ZY; Guo QL
    Mol Pharmacol; 2012 Nov; 82(5):958-71. PubMed ID: 22909797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth.
    Pizzi M; Piazza F; Agostinelli C; Fuligni F; Benvenuti P; Mandato E; Casellato A; Rugge M; Semenzato G; Pileri SA
    Oncotarget; 2015 Mar; 6(9):6544-52. PubMed ID: 25788269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.
    Prins RC; Burke RT; Tyner JW; Druker BJ; Loriaux MM; Spurgeon SE
    Leukemia; 2013 Oct; 27(10):2094-6. PubMed ID: 23900138
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.
    Quotti Tubi L; Gurrieri C; Brancalion A; Bonaldi L; Bertorelle R; Manni S; Pavan L; Lessi F; Zambello R; Trentin L; Adami F; Ruzzene M; Pinna LA; Semenzato G; Piazza F
    J Hematol Oncol; 2013 Oct; 6():78. PubMed ID: 24283803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
    Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F
    Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo.
    Richter A; Sender S; Lenz A; Schwarz R; Hinz B; Knuebel G; Sekora A; Murua Escobar H; Junghanss C; Roolf C
    BMC Cancer; 2020 Mar; 20(1):184. PubMed ID: 32131762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined SRPK and AKT pharmacological inhibition is synergistic in T-cell acute lymphoblastic leukemia cells.
    Siqueira RP; Caetano MMM; de Souza LÂ; Dos Passos PMS; Simaroli NB; Barros MVA; de Souza APM; de Oliveira LL; Silva-Júnior A; Fietto JLR; Teixeira RR; Teixeira FR; Bressan GC
    Toxicol In Vitro; 2020 Jun; 65():104777. PubMed ID: 31962201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia.
    Quotti Tubi L; Canovas Nunes S; Brancalion A; Doriguzzi Breatta E; Manni S; Mandato E; Zaffino F; Macaccaro P; Carrino M; Gianesin K; Trentin L; Binotto G; Zambello R; Semenzato G; Gurrieri C; Piazza F
    Leukemia; 2017 Feb; 31(2):292-300. PubMed ID: 27479180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Druggability of the CK2 inhibitor CX-4945 as an anticancer drug and beyond.
    Kim J; Kim SH
    Arch Pharm Res; 2012 Aug; 35(8):1293-6. PubMed ID: 22941473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of casein kinase 2 prevents growth of human osteosarcoma.
    Takahashi K; Setoguchi T; Tsuru A; Saitoh Y; Nagano S; Ishidou Y; Maeda S; Furukawa T; Komiya S
    Oncol Rep; 2017 Feb; 37(2):1141-1147. PubMed ID: 27959425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.